AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02600741 — intervention group
Intervention type: OTHER
Intervention: Caregiver psycho-education and skills training
Description: Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.
Study NCT02600741 — intervention group
Intervention type: OTHER
Intervention: Caregiver support available at the study site
Description: Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Paliperidone palmitate
Description: Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Chlorpromazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Droperidol
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Fluphenazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Haloperidol
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Loxapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Perphenazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Pimozide
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Prochlorperazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Thiothixene
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Thioridazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Trifluoperazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Aripiprazole
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Asenapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Clozapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Iloperidone
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Olanzapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Paliperidone
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Quetiapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Risperidone
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT02600741 — intervention group
Intervention type: DRUG
Intervention: Ziprasidone
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
Study NCT04026971 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.
Description: This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.
Study NCT04026971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.
Description: This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.
Study NCT04965168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification of the lens
Description: all patients underwent phacoemulsification and IOL implantation for immature cataract extraction
Study NCT01767012 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polylens EC-HY10-PAL (coated)
Description: hydrophobic acrylic IOL with modified surface properties (Heparin-coating)
Study NCT01767012 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polylens EC-Y10-PAL (uncoated)
Study NCT00156910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
Study NCT00156910 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
Study NCT02626936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
Study NCT01896739 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eutravac
Study NCT01896739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eutravac
Study NCT03419936 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic biopsy
Description: 1. Pre-operation (initial diagnosis) Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~2. Post-subtotal gastrectomy (After 6 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~3. Post-subtotal gastrectomy (After 12 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~4. Post-subtotal gastrectomy (After 24 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.
Study NCT00516412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Study NCT00516412 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: molecular response by PCR
Description: Bone marrow and peripheral blood samples are collected periodically and analyzed for molecular response by PCR. Molecular studies are also performed on DNA level formalin-fixed paraffin-embedded tissue
Study NCT04564066 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod IV
Description: intravenous infusions of efgartigimod
Study NCT04564066 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Description: subcutaneous injections of efgartigimod PH20 SC
Study NCT02410096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise challenge in a cold chamber
Description: Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
Study NCT02410096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise challenge in a cold chamber
Description: Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
Study NCT02410096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Methacholine challenge
Description: Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
Study NCT02410096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine challenge
Description: Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
Study NCT02410096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oil supplementation verum
Description: Patients and subjects will take double blind an oil supplementation with middle-chain and polyunsaturated fatty acids for four weeks
Study NCT02410096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oil supplementation placebo
Description: Patients and subjects will take double blind sunflower oil for four weeks
Study NCT03351439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Group 2 - Zopiclone 7.5 mg orally, nightly for 7 days
Study NCT03351439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Group 3 - Gabapentin 600 mg orally, 1 hour pre-operatively and 600 mg orally, 8 hours post-operatively
Study NCT03351439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: Group 4 - Celebrex 400 mg PO, 1 hour pre-operatively
Study NCT03351439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet
Description: Standard of Care
Study NCT03351439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percocet
Description: Standard of Care
Study NCT01019928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: 95 mg, oral solution, single dose
Study NCT01019928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to AZD1386
Description: Placebo, oral solution, single dose
Study NCT03351439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn
Description: Standard of Care
Study NCT03351439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naprosyn
Description: Standard of Care
Study NCT02945605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Vestibular Rehabilitation
Description: Two visits/week for a maximum of 5 weeks will be provided with the approximate duration for each visit estimated at 50-60 minutes. Consistent with a previously validated framework for exercise prescription in patients with concussion, the exercises provided by the treating therapist can be classified into five main exercise categories:~1. Eye-Head coordination, gaze stability and convergence exercises~2. Sitting balance~3. Standing static balance (i.e. feet-in-place)~4. Dynamic balance (feet moving, but not walking)~5. Ambulation (gait exercises)~6. Other exercises: Sport specific exercises, Canalith repositioning maneuvers are recorded as others
Study NCT02945605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard care as directed by a physician.
Study NCT02553317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Description: * First day of treatment: 10 mg intravenous (i.v.) injection prior to plasma exchange (PE) followed by a 10 mg subcutaneous (s.c.) injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily 10 mg s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily 10 mg s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression.
Study NCT02945605 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard care as directed by a physician.
Study NCT03805503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 1% Injectable Solution
Description: standard CSE procedure in outpatients for inguinal hernia. The first spinal dose of chloroprocaine 1% to start with is 50mg. This dose has been successfully used for spinal anesthesia in hernia repair outpatients to reach an adequate analgesia. 2,5 microgram of sufentanil will be added for prolongation of the analgesia. The testing interval is 2 mg.~Efficacy of the analgesia will be evaluated:~Successful : sensory block at or above T6 dermatome bilateral at the beginning of surgery without additional analgesia during surgery. Unsuccessful: sensory block under T6 dermatome bilateral and/or VAPS is more than 10 mm at the beginning of surgery what necessitates additional epidurals analgesia.~Patients who indicate an ineffective result will receive a rescue treatment by the administration of 5 ml chloroprocaine 3% epidural every 5 minutes with maximum of 30ml. When CSE fails, general anesthesia will be performed.
Study NCT04057469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulobuterol Hydrochloride
Description: The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
Study NCT04057469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal patch
Description: The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
Study NCT03426566 — intervention group
Intervention type: OTHER
Intervention: retrospective observational study with no intervention
Description: no intervention
Study NCT02553317 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * First day of treatment: i.v. injection prior to PE followed by a s.c. injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression.
Study NCT04099849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet-ZnBfR: Zinc biofortified rice-based diet
Description: Diet-ZnBfR: Zinc biofortified rice-based diet
Study NCT04099849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet- CR: Conventional rice-based diet
Description: Diet- CR: Conventional rice-based diet
Study NCT04099849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
Description: CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
Study NCT04260061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: training systems
Description: Participants will receive 18 intervention sessions for about 6-9 consecutive weeks in a clinical setting (75 minutes per session, 2-3 sessions per week). For each intervention session, participants will first receive 10 minutes of warm-up followed by 50 minutes robotic-assisted training (robotic-assisted training includes 10 minutes passive training mode, 20 minutes active training mode, and 20 minutes robot-participant interactive training mode) and then 15 minutes of functional activity without robotic-assisted (content will be related to robotic-assisted training and will be based on the action function and preferences of the participants).
Study NCT02703987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented infant milk formula
Study NCT02703987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-fermented infant milk formula
Study NCT00229229 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low glycemic load diet
Description: A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
Study NCT00229229 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Canada Food Guide Diet
Description: A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
Study NCT00229229 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low glycemic index diet
Description: A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
Study NCT00229229 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low carbohydrate diet
Description: A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
Study NCT03338868 — intervention group
Intervention type: OTHER
Intervention: Quality of life
Description: assessed by the Nottingham Health Profile
Study NCT03338868 — intervention group
Intervention type: OTHER
Intervention: Psychological Well-Being
Description: assessed by the Hospital Anxiety and Depression Scale
Study NCT03338868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: Blood tests included serum glucose, triglyceride, high-density lipoprotein cholesterol (HDL-C), and uric acid levels. Blood samples were collected from the patients after one night of fasting.
Study NCT01409824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDSS
Description: Clinical Decision Support System
Study NCT02626936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
Study NCT01315002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal nicotine patch
Description: 7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)
Study NCT01315002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Placebo patch
Study NCT02626936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 Platinum glucose sensor
Study NCT03436771 — intervention group
Intervention type: GENETIC
Intervention: JCAR017
Description: No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival.
Study NCT03436771 — intervention group
Intervention type: GENETIC
Intervention: JCARH125
Description: No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival.
Study NCT04576247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise
Description: The 12-week intervention will build upon an ongoing resistance exercise program for cancer patients and survivors at the University of Colorado's Anschutz Health and Wellness Center. Resistance exercise will be led by certified cancer exercise specialists who provide individualized exercise programs to cancer patients and survivors. Exercise sessions are progressive, target all major muscle groups, are 50 minutes in duration, and completed 2x/week.~The intervention will also include 3 self-directed moderate-intensity aerobic exercise sessions/week, building to 50 minutes at 60% heart rate maximum (determined at baseline). Target exercise will be achieved by a gradual progression of exercise duration over the first four weeks of the program.
Study NCT01530555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG, Thymoglobuline (Genzyme)
Description: 1. Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~2. Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months
Study NCT01372449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but \<60 kg, and 6 mg for subjects weighing ≥ 20 kg but \< 40kg.
Study NCT02736877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumera Microscope with OCT RESCAN
Description: corneal transplantation guided by Lumera Microscope with OCT RESCAN
Study NCT02736877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Microscope
Description: corneal transplantation guided by Conventional Microscope
Study NCT02626936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accu Chek Combo insulin pump